Skip to main content

Association between perfluoroalkyl and polyfluoroalkyl substances and response to the COVID-19 vaccine in a pediatric prospective observational cohort in Arizona

July 16, 2026
Image
Dr. Karen Lutrick and Shawn Beitel, MSc, pictured at the AZHEROES program.

Dr. Karen Lutrick and Shawn Beitel, MSc, pictured at the AZHEROES program.

Perfluoroalkyl and polyfluoroalkyl substances, collectively known as PFAS, are synthetic chemicals commonly found in consumer items like non-stick cookware, food packaging, and athletic gear because of their heat-, stain-, and water-resistant properties. Previous research has linked PFAS exposure to elevated blood lipid levels, certain cancers, and decreased antibody responses to infection and vaccinations. 

The goal of this study was to study whether PFAS levels in children affect antibody response to COVID-19 vaccination. The researchers found that, like other vaccines, children with higher levels of PFAS in their blood had weaker antibody responses to COVID-19 vaccination. 

  

What are PFAS and how do they affect our health? 
  PFAS are commonly known as “forever chemicals” that can remain in our bodies and the environment for thousands of years. They’re commonly found in everyday products like lotions and perfumes, where they can leach into our bodies and remain there for extended periods of time, though inhalation and ingestion remain the primary routes of exposure. 

  

In the human body, PFAS can disrupt hormone production and balance, negatively affect reproductive organs, and even be linked to certain kinds of cancer. Amongst these disruptions are changes to the immune system, specifically affecting the body’s antibody response to vaccinations. The COVID-19 vaccine grants us ‘immunity’ to the COVID-19 virus by instructing our cells to make a non-pathogenic copy of a protein on the outside of the virus. Upon seeing this protein copy, the immune system will create antibodies in preparation for the real thing, allowing our bodies to more easily fight off diseases and infections. 

Previous research demonstrates an inverse relationship between PFAS exposure and vaccine antibody responses in children. However, there is some variation depending on the amount of exposure, specific vaccine type, and specific PFAS compound. Additionally, there appears to be less of a relationship between PFAS exposure and antibody response in adults, though there are still knowledge gaps. 

  

What were the methods of data collection and analysis? 

The source of data for this study was the AZ-HEROES (Arizona Healthcare, Emergency Response and Other Essential Workers Surveillance) program, focused on Arizona adults with high occupational exposure to PFAS and other hazardous materials who were being studied to observe the epidemiological and immunological effects of SARS-CoV-2 infection. This initial adult cohort wasn’t used for the study, with a pediatric cohort being enrolled a year later and consisting of children of the AZ-HEROES participants and children from the general community. 

  

To be included for analysis, participants received the full mRNA COVID-19 vaccine course, were subject to a blood draw within 60 days of the final vaccine dose, and had no previous history of a SARS-CoV-2 infection at the time of their blood draw. 

  

The blood was then sent to the University of Arizona Genetics Core laboratory to measure antibody binding to two regions of the SARS-CoV-2 spike protein produced in response to the vaccine: the receptor-binding domain (RBD) and S2 subunit domain (S2). Levels of these antibodies essentially measureimmune response to vaccination. 

  

What were the results of this study? 

The researchers performed linear regression after cleaning up the data and accounting for outliers, finding that an increase in PFAS concentration in the blood could decrease antibody binding to the protein receptor-binding domain (RBD). On average, antibody binding would decrease by 5% for every standard deviation increase in PFAS concentration. Individuals in the third quartile saw antibody binding decrease by an average of 9.1%, while individuals in the fourth quartile saw an average decrease of up to 10.7%. 

  

This means there’s a significant association between increased serum PFAS concentration and a reduced antibody response to the COVID-19 mRNA vaccine in a cohort of children aged 1–16 years in Arizona, USA. 

  

How is this study important for the future? 

This is the first study in children to assess the relationship between serum PFAS concentration and antibody response to COVID-19 vaccination, contributing results to the growing literature surrounding PFAS exposure as it relates to decreased antibody response. This will form the foundation for future research regarding the clinical significance of these findings and possible implications for health outcomes regarding PFAS exposure and the immune system. 
   
To read the entire article, click here.